Compare Teradyne, Inc. (TER) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Teradyne, Inc. vs Tilray Brands Inc — how do they compare? Teradyne, Inc. trades at $404.7 (market cap $62.34B), while Tilray Brands Inc trades at $3.4 (market cap $530.54M). The key difference: Teradyne, Inc. is far larger — about 117.5× Tilray Brands Inc's market cap, and Teradyne, Inc. pays a 0.13% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Teradyne, Inc. for 37 Days and Tilray Brands Inc for 31 Days on average.
| TER | TLRY | |
|---|---|---|
Market Cap | $62.34B | $530.54M |
Volume | 3,368,404 | 9,099,075 |
Sector | Technology | Health |
52-Week High | $483.84 | $21.00 |
52-Week Low | $132.05 | $3.57 |
Typical Hold Time | 37 Days | 31 Days |
Enterprise Value | $62.08B | $684.46M |
Dividend Yield | 0.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Teradyne (TER) trades at $411.78, down 4.31% today but maintains strong technical momentum with bullish moving averages and support at $407. The company demonstrates robust fundamentals with three consecutive earnings beats, 25.77% net margins, and 36.66% ROE. Recent product launches including Magnum E2 and Iris 100 position TER to capitalize on AI-driven semiconductor testing demand. Revenue is projected to grow from $3.19B in 2025 to $4.5B in 2026 according to company guidance.
TER presents a compelling growth opportunity with dominant positioning in semiconductor testing equipment and strong AI tailwinds. However, elevated valuation multiples (P/E 54.77, P/S 14.11) require continued execution. Key risks include semiconductor cycle volatility and competitive pressure from KLAC and COHU. Analyst consensus remains bullish with $461.50 price target representing 12% upside from current levels.
TLRY trades at $3.465, down 6.73% on the day and near 52-week lows, reflecting persistent bearish sentiment. The stock shows weak technical momentum with oversold RSI readings but faces fundamental challenges including consecutive quarterly earnings misses, negative profit margins, and declining revenue growth. Recent news highlights the company's struggles with profitability despite record annual revenue, with shares down over 50% year-to-date as investors question the cannabis company's path to sustainable growth.
TLRY presents a high-risk opportunity with significant downside protection from its low P/B ratio of 0.33, but requires substantial operational improvement to justify investment. The bullish case hinges on potential marijuana reform catalysts and BrewDog integration progress, while risks include ongoing losses, competitive pressures, and execution challenges in a volatile regulatory environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
